Initial clinical experience of selective coronary angiography using one prolonged injection and a 180° rotational trajectory

Catheterization and Cardiovascular Interventions

Volumn 70, Issue 2, 2007, Pages 190-196

  Garcia, Joel A ^a   Chen, S Y James ^a   Messenger, John C ^a   Casserly, Ivan P ^b   Hansgen, Adam ^a   Wink, Onno ^c   Movassaghi, Babak ^d   Klein, Andrew J ^a   Carroll, John D ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c PHILIPS HEALTHCARE   (United States)

^d PHILIPS RESEARCH LABORATORIES   (Netherlands)

Author keywords

ANGO angiography coronary; CONT contrast media; HEMO hemodynamiocs

Indexed keywords

IODIXANOL;

ANGIOCARDIOGRAPHY; AORTA PRESSURE; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; DIASTOLE; FEMALE; HEART RATE; HEAT SENSATION; HEMODYNAMICS; HUMAN; LEFT CORONARY ARTERY; MALE; RADIATION EXPOSURE; RIGHT CORONARY ARTERY; SIDE EFFECT; SYSTOLE; THREE DIMENSIONAL IMAGING;

AORTA; BLOOD PRESSURE; CONTRAST MEDIA; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; EQUIPMENT DESIGN; FEASIBILITY STUDIES; FEMALE; HEART RATE; HUMANS; IMAGING, THREE-DIMENSIONAL; INJECTIONS; MALE; RADIATION DOSAGE; RADIOGRAPHIC IMAGE INTERPRETATION, COMPUTER-ASSISTED; ROTATION; TIME FACTORS; TRIIODOBENZOIC ACIDS;

EID: 34249789702     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.21054     Document Type: Article

References (22)

1. Spears JR, et al. The minimum error in estimating coronary luminal cross-sectional area from cineangiographic diameter measurements. Cathet Cardiovasc Diagn 1983;9:119-128.
2. Topol EJ, Nissen SE. Our preoccupation with coronary luminology. The dissociation between clinical and angiographic findings in ischemic heart disease. Circulation 1995;92:2333-2342.
3. Galbraith JE, Murphy ML, de Soyza N. Coronary angiogram interpretation. Interobserver variability. JAMA 1978;240:2053-2056.
4. Scanlon PJ, et al. ACC/AHA guidelines for coronary angiography. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on Coronary Angiography). Developed in collaboration with the Society for Cardiac Angiography and Interventions. J Am Coll Cardiol 1999;33:1756-1824.
5. Maddux JT, et al. Randomized study of the safety and clinical utility of rotational angiography versus standard angiography in the diagnosis of coronary artery disease. Catheter Cardiovasc Interv 2004;62:167-174.
6. Rasche V, et al. Three-dimensional X-ray coronary angiography in the porcine model: A feasibility study. Acad Radiol 2006;13: 644-651.
7. Rasche V, et al. Automatic selection of the optimal cardiac phase for gated three-dimensional coronary X-ray angiography. Acad Radiol 2006;13:630-640.
8. Movassaghi B, et al. A quantitative analysis of 3-D coronary modeling from two or more projection images. IEEE Trans Med Imaging 2004;23:1517-1531.
9. Movassaghi B, et al. In vivo three-dimensional reconstruction of coronary stents based on motion compensated X-ray angiograms: First in human results. Am J Cardiol 2006;98: 104 M.
10. Garcia J, et al. Four-dimensional gated reconstructed images of the coronary arteries based on rotational coronary angiography: First in human results. Am J Cardiol 2006;98(8)(98):104 M.
11. Roriz R, et al. Comparison of iodixanol (Visipaque) and ioxaglate (Hexabrix) in coronary angiography and ventriculography: A double-blind randomized study. J Radiol 1999;80:727-732.
12. Morris TW. A review of coronary arteriography- and contrast media-induced ventricular fibrillation. Acta Radiol Suppl 1995; 399:100-104.
13. Klow NE, et al. Iodixanol in cardioangiography in patients with coronary artery disease. Tolerability, cardiac and renal effects. Acta Radiol 1993;34:72-77.
14. Pedersen HK, et al. Contrast-medium-induced ventricular fibrillation: Arrhythmogenic mechanisms and the role of antiarrhythmic drugs in dogs. Acad Radiol 1995;2:1082-1088.
15. Armstrong SJ, et al. Ventricular fibrillation in coronary angiography: What is the role of contrast medium? Eur Heart J 1989;10:892-895.
16. Jorgensen NP, et al. Safety and tolerability of iodixanol in healthy volunteers with reference to two monomeric X-ray contrast media. Eur J Radiol 1992;15:252-257.
17. Nossen JO, et al. Experience with iodixanol, a new nonionic dimeric contrast medium. Preliminary results from the human phase I study. Invest Radiol 1990;25(Suppl 1):S113-S114.
18. Murdock DK, et al. Characterization of ventricular fibrillation during coronary angiography. Am J Cardiol 1985;55:249.
19. Murdock DK, et al. Ventricular fibrillation during coronary angiography: An analysis of mechanisms. Am Heart J 1985;109: 265-273.
20. Wisneski JA, et al. Comparison of low osmolality ionic (ioxaglate) versus nonionic (iopamidol) contrast media in cardiac angiography. Am J Cardiol 1989;63:489-495.
21. Andersen PE, et al. Iodixanol and ioxaglate in cardioangiography: A double-blind randomized phase III study. Clin Radiol 1993;48:268-272.
22. Bertrand ME, et al. Influence of a nonionic, iso-osmolar contrast medium (iodixanol) versus an ionic, low-osmolar contrast medium (ioxaglate) on major adverse cardiac events in patients undergoing percutaneous transluminal coronary angioplasty: A multicenter, randomized, double-blind study. Visipaque in Percutaneous Transluminal Coronary Angioplasty [VIP] Trial Investigators. Circulation 2000;101:131-136.